

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.
Drug information is given in full under the generic name,
with a cross-reference from the trade name.

- 5-HT. See *Serotonin*.
- 5-HTT. See *Serotonin transporter protein*.

- Abilify (aripiprazole), 193, 236-237
- Acetaminophen, 108t
- Acetylcholine, 72t
- Acetylcholine antagonists, 232
- Acetylcholine receptor blockers. See *Muscarinic acetylcholine receptor blockers*.
- ACTH. See *Adrenocorticotrophic hormone*.
- Activity level, 13
 - in different types of affective disorders, 15t
- Acute therapeutic index, 123-133
- Adaptation to stressful situations, 41t
- Adolescents, suicide and, 19, 53-54
- Adrenal glands, 70
- Adrenocorticotrophic hormone (ACTH), 69, 70, 71, 72t
- Adverse effects of antidepressants, 60, 88t-96t. See also *specific drugs*.
 - treatment of, 244-249
- Affect of patient, 15t, 16-17, 41t
 - in diagnosis of depression, 41t
 - in different types of disorders, 15t
- Affective circuits in brain, 63, 64
- Age, drug response and, 82-83
- Age of onset
 - atypical clinical depression, 13
 - melancholic (classic) major depression, 13, 26, 27t
- Agitation, 14t, 40
- Agranulocytosis, 184
- Alcohol intake
 - antidepressant potentiation of effects of, 136
 - communicating with patient about, 51
 - depression and, 16, 23, 28
 - questioning for diagnosis, 39
 - self-medication with, 23
 - suicide and, 46t
 - TCAs and, 136
- Alfentanil, 109t
- Alpha-1-adrenergic receptor blockers, 84t, 106
 - adverse effects of, 246
 - drugs with this action, 84t, 183
 - TCAs and, 136
- Alprazolam, 109t, 168
- Alzheimer's, comorbidity with depression, 43
- Amitriptyline (Elavil). See also *Mixed reuptake and neuroreceptor antagonists*.
 - action mechanisms, 80t, 84t
 - action sites, 99, 104
 - cost of, 143
 - CYP enzymes and, 107, 108t
 - dosage, 146t
 - drug interaction with, 136

- Amitriptyline (Elavil) (*continued*)
 frequency of prescriptions for, 156t, 160
 polydrug actions of, 99, 100, 100t
 relative binding affinity, 99, 104
- Amoxapine (Ascendin). See also *Mixed reuptake and neuroreceptor antagonists*.
 action mechanisms, 80t
 dosage, 146t
- d-Amphetamine, 238
- Amygdala, 65, 66, 68
- Anafranil. See *Clomipramine*.
- Anatomy, brain, 63-67, 64, 66
- Anorexia, 88t, 90t, 92t, 94t, 95t, 245
 treatment options for, 245
- Antiarrhythmic drugs, increased potentiation with TCAs, 136
- Anticholinergics, for diarrhea, 245
- Anticholinergic withdrawal syndrome, 114, 114t
- Antidepressant drug classes, 77-79, 80t-81t. See also *specific drug classes*.
 dopamine and norepinephrine reuptake inhibitors, 80t, 185-189
 mixed reuptake and neuroreceptor antagonists, 80t, 157-160
 monoamine oxidase inhibitors (MAOIs), 80t, 189-192
 norepinephrine selective reuptake inhibitors (NSRIs), 80t, 100-102, 161-163
 serotonin (5-HT_{2A} and 2C) and alpha-2 norepinephrine receptor blocker, 80t, 183-185
 serotonin-2A (5-HT_{2A}) receptor blocker and weak serotonin uptake inhibitors, 80t, 178-182
 serotonin and norepinephrine reuptake inhibitors (SNRIs), 80t, 174-178
 serotonin selective reuptake inhibitors (SSRIs), 80t, 163-174
- Antidepressant drug development, 77-121, 232
 antidepressant withdrawal syndrome, 114-117
 cytochrome P450 (CYP) enzymes, 106-111
 drug classes and actions, 80t-81t, 81-82, 84t-96t
 goal of, 79-81, 101
 half-life and, 112-113
 newer antidepressants, launch dates of, 78
 next generations of (future development), 232
 pharmacodynamic drug-drug interactions and, 106
 pharmacodynamic principles in, 97-106, 111-112
 pharmacodynamics, pharmacokinetics, and interindividual variability in, 82-87, 137, 202
 rational drug development, 79-82
 relative binding affinity and, 87, 99, 102-105
- Antidepressant drug therapy. See also *specific drugs and drug types*.
 action mechanisms, 80t-81t, 84t-85t
 action sites, 86t
 adherence to, 60, 60t
 adverse effects, 60, 88t-96t, 97-98
 treatment of, 244-249
 algorithm for treatment decisions, 203
 antagonist and indirect agonist actions of drugs, 86t, 97
 assessing adequacy of, 202, 203, 205
 augmentation strategies, 227, 228-229, 235-239
 benefits of, 58-59
 binding affinity and, 87
 blockade or antagonism, clinical consequences of, 86t
 brain regions affected by, 65-67, 66, 72
 clinical trials, 226-241
 combination therapy
 with antipsychotics, 242
- Antidepressant drug therapy, combination therapy (*continued*)
 with anxiolytics, 241
 combinations of antidepressants, 227, 239-241
 combinations to be avoided, 241
 with mood stabilizers, 242
 with other drugs, 141, 236-239, 241-242
 in STAR*D study, 227
 communicating with patient about, 48-54, 57-58, 58t
 compliance with, 60, 60t
 noncompliance with, 60, 60t, 61t
 continuation therapy, 205-209
 cost of, 57, 124t
 CYP enzymes and, 106-111, 107, 108t-110t
 dosage, 56, 144-150, 146t-149t
 adjustments in, 225-226
 adverse effects and, 244-249
 augmentation strategies and, 235
 half-life and, 112-113
 monitoring, 145-150
 optimum, 144-150
 overdose, 123-124
 safety considerations, 123-133
 for specific drugs, 146t-149t
 starting, 144
 drug-drug interactions, 106, 108t-110t, 136
 mechanisms of, 213-214
 multiple medication use and, 211-222
 newer antidepressants and, 215
 "therapeutic," 235-239
 duration of, 56, 205-209, 223-224
 efficacy of, 138-143, 166t-167t
 brain metabolic changes and, 66
 dosage and, 144-150
 lag time before, 204
 maintenance, 140, 142
 overall acute, 139, 140
 prophylactic, 140, 142-143
 response rate, 139-141
 spectrum of, 139, 141-142
 evaluation of, 65-67, 66, 155-200, 223
 failure of, 225-241
 alternative medication regimes, 157, 160, 161, 203
 in treatment algorithm, 203
 follow-up visits, 201-209
 four "D's" of, 56-61
 frequency (%) of prescriptions, 155, 156t
 goals of, 58, 60-61
 half-lives in, 112-113, 115
 Hamilton Depression Rating Scale in, 58t, 65, 134, 205, 206-209
 inadequate responses to, 223-255
 alternative medication regimes, 157, 160, 161, 203
 augmentation strategies, 227, 228-229, 235-239
 combination treatments, 241-242
 dose adjustment and, 225-226
 other somatic treatments, 242-244
 STAR*D study and, 226-241
 switching strategies, 227, 228-229, 233-235
 indefinite therapy, 209-210

Antidepressant drug therapy (*continued*)
 initiation and follow-up, 48-54, 201-205
 initiation decision, 55-61
 interindividual variability in response to, 82-87, 137, 202
 maintenance therapy, 209-210
 management of treatment, 201-210
 multiple medication use (MMU) and, 211-222
 neurotransmitters involved with, 67-68
 noncompliance with, 60, 60t, 61t
 other medications with, 211-222
 partial response in, 223-255
 patient compliance/noncompliance with, 60, 60t, 61t
 patient concerns about, 49-51, 57
 patient education about, 60-61
 pharmacodynamic principles and, 97-106
 placebo response and, 58-59
 polydrug actions of, 100-101, 110t
 prophylactic therapy, 140, 142-143, 209-210
 response rate, 58, 58t
 response rate, communicating about, 58, 58t
 response vs remission with, 58, 58t
 responses to, 223-255
 dose adjustment and, 225-226
 failed trial, 225
 full success (remission), 223
 partial success, 223-224
 safety of, 123-137
 acute therapeutic index, 123-133
 communicating with patient about, 57-58
 long term, 133
 suicidality and, 134-136
 selection of antidepressant, 56, 125-153, 192-194
 simplicity in, 124t, 144-150
 STEPS criteria, 56, 123-153, 124t, 125t-132t. See also *STEPS criteria*.
 suicide and, 134-136
 black box warning, 135
 children and adolescents, 23, 53-54, 134-135
 decrease with therapy, 23, 24, 136
 switching strategies, 227, 228-229, 233-235
 therapeutic drug monitoring (TDA) in, 125t, 145
 tolerability of, 137-138, 141
 communicating with patient about, 57-58
 treatment options for adverse effects, 244-249
 anorexia, 245
 confusion, 245
 constipation, 245
 diaphoresis, 245
 diarrhea, 245
 dizziness, 246
 drowsiness, 246-247
 dry mouth, 247
 fatigue, 247
 half-life and, 249
 hyperphagia, 247-248
 insomnia, 248
 nausea, 248
 nervousness, 248
 referral to psychiatrist, 249

Antidepressant drug therapy, treatment options for adverse effects (*continued*)
 sexual dysfunction, 248-249
 vision disturbance, 249
 in treatment-refractory patients, 141
 trial of, 43, 59-60
 length of, 56, 59-60
 withdrawal syndrome, 114-117, 114t, 115t, 116
 Antihistamines, 179
 Antihypertensive drugs
 as cause of depression, 16, 39
 increased potentiation with TCAs, 136
 Antipsychotic drugs
 antidepressants with, 193, 242
 atypical, 193
 Anxiety disorders, SSRI efficacy for, 164, 166t-167t
 Anxiolytics, antidepressants with, 241
 Apathy, 31
 treatment of, 238
 Aphrodyne (yohimbine), 248
 Aplenzin, 80t, 133. See also *Bupropion*.
 Appetite changes, 13
 as antidepressant side effect, 88t, 90t, 92t, 96t, 97-98, 184
 in different types of affective disorders, 15t
 Aripiprazole (Abilify), 193, 236-237
 Arrhythmias, ventricular, 101, 124
 Ascendin. See *Amoxapine*.
 Atherosclerosis, 69
 Attention. See *Concentration/attention*.
 Attention deficit/hyperactivity disorder, 186
 Atypical clinical depression
 age of onset in, 13
 monoamine oxidase inhibitors for, 192
 symptoms in, 13, 15t
 Augmentation strategies for antidepressants, 227, 228-229, 235-239
 Aventyl. See *Nortriptyline*.
 Behavior (patient's), observation of, 31, 40, 41t, 42t
 Benzodiazepines, 248
 Benzotropine, 219
 Beta-blockers, 245, 248
 Binding affinity, relative, 87, 99, 102-105
 Bipolar disorder
 diagnosing, 15t, 16-17
 family history of, 17, 40, 242
 lithium/mood stabilizers for, 40, 242
 vs unipolar disorder, 15t, 16-17
 Blood cell count, 40
 Blood pressure. See also *Hypotension*.
 increase with antidepressants, 133, 161, 175
 monitoring, 192
 potentiation of antihypertensive drug effects, 136
 Brain anatomy and physiology, 63-68, 64, 66
 amygdala, 65, 66, 68
 antidepressant therapy and, 65-67, 66, 72
 circuits, 63, 64
 dorsolateral prefrontal cortex (DLPFC), 65, 72
 hippocampus, 65, 66, 76-78
 lateral orbital prefrontal cortex (LOPFC), 64

- Brain anatomy and physiology (*continued*)
 neurogenesis and, 71, 72t
 neurotransmitters and receptors, 67-72, 72t
 ventromedial prefrontal cortex (VMPFC), 64, 67, 69, 72
- Brain-derived neurotrophic factor (BDNF), 71, 72t
- Brain imaging
 diagnosis and, 40
 structures involved in depression and, 63, 64-67
- Brain tumors and lesions, 67
- Briquet's syndrome, 39-40
- Bupropion (Wellbutrin, Zyban), 80t, 185-189. See also *Dopamine and norepinephrine reuptake inhibitors*.
 action mechanism, 80t, 84t
 action sites, 105
 advantages of, 185-186
 adverse effects, 92t-93t, 96t
 in combination therapy, 186, 187, 240
 CYP enzymes and, 108t, 137, 187-188
 disadvantages of, 186-189
 dosage, 133, 144, 145, 147t, 150, 186-187, 188-189
 seizures and, 133, 144, 145, 186-187, 189
 drug interactions with, 18, 185, 187
 efficacy, 166t, 186
 formulations, 80t, 133, 147t, 150, 188
 extended-release (XL), 147t, 150, 156t, 188
 hydrobromide (Aplenzin), 80t, 133, 188
 immediate-release, 147t, 150, 156t, 188
 sustained-release, 147t, 150, 156t, 188
 frequency of prescriptions for, 113, 150, 156t
 half-life of, 113, 188
 indications for, 189
 launch date of, 78
 relative binding affinity, 105
 safety, 124-133, 185, 186-187
 seizure risk with, 133, 144, 145, 186-187, 189
 sexual dysfunction, as treatment for, 248
 sexual function and, 138, 186
 for smoking cessation, 186, 189
 in STAR*D study, 227, 228, 233-234, 236
 STEPS criteria for, 124-133, 131t, 185-189
 sustained release (Wellbutrin SR), 78
 switching to, 187
 TDM for, 187
 tolerability, 185-186
- Bupropion (Buspar)
 for anxiety disorder, 239
 as augmentation strategy, 227, 236, 238-239, 240
 CYP enzymes and, 109t
 for sexual dysfunction, 248
- Cancer, 16, 69
 comorbidity with depression, 42, 43
- Cardiotoxicity, TCAs and, 124, 158
- Catecholamines, 69, 70
- Caudate nucleus, 63, 64
- Celexa. See *Citalopram*.
- Children, suicide risk with antidepressants, 19, 134-135
 communicating about, 53-54
- Chlorpheniramine, 108t, 109t
- Chlorpromazine, 108t
- Cholinergic rebound, 114, 114t
- Chronic depression, 19, 20, 21. See also *Clinical depression*.
- Chronic disease, comorbidity with depression, 43
- Chronic medical illness, 213, 214t
- Chronic pain, 157, 160, 214t
- Cigarette smoking
 bupropion for cessation of, 186, 189
 in depressed individuals, 23-25
- Citalopram (Celexa). See also *Serotonin selective reuptake inhibitors (SSRIs)*.
 action mechanism, 80t
 action sites, 102, 107, 107
 adverse effects, 88t-89t, 94t, 168
 in combination therapy, 240
 CYP enzymes and, 108t, 110t, 111, 169, 174-175, 178, 215
 dosage, 146t
 starting, 144, 146t, 164
 efficacy, 166t, 171t
 compared with other drugs, 125t, 127t, 128t, 155, 157
 escitalopram vs, 169-172, 171t, 172t
 frequency of prescriptions for, 156t
 launch date of, 78
 as racemate, 169-172, 171t, 172t
 relative binding affinity, 102
 remission rate with, 59, 61, 231t
 response rate, 173
 in STAR*D study, 28, 61, 165, 186, 226-227, 228, 230, 233-234, 239
 suicide risk ratio, 135
 withdrawal syndrome, 115, 168
- Clarithromycin, 109t
- Classic major depression. See *Melancholic depression*.
- Clearance of drugs, 215-216. See also *Half-life*.
- Clinical depression. See also *Antidepressant drug therapy; Treatment of depression*.
 atypical, 13
 comorbidities, 42, 43
 cost of, 19, 22t, 25-26, 26
 diagnosis of, 11-17, 14t, 15t, 31-43. See also *Diagnosis*.
 DSM-IV criteria for, 13, 14t
 early diagnosis and treatment, value of, 19, 20, 21
 forms of, 13
 hospitalization for, 45, 47, 48
 key facts about, 19, 22
 melancholic, 13, 14t
 neuroscience basis of, 63-75
 prognosis, 25, 28
 recommendation of antidepressant therapy in, 59
 risk factors for, 26-28, 27t
 signs and symptoms, 12-15, 14t, 15t
 substance abuse/smoking and, 23-25
 suicide and, 19-23, 23t
 systemic consequences of, 69
 treatment algorithm, 203
- Clinical trials
 communicating with patient about, 57-58, 58t
 double-blind crossover (switching) studies, 234
 STAR*D, 28, 61, 139, 141-142, 186, 193, 226-241

- Clomipramine (Anafranil). See also *Mixed reuptake and neuroreceptor antagonists*.
 action mechanism, 80t
 CYP enzymes and, 108t
 dosage, 146t
 efficacy, 140
 response rate, 140, 157
- Clonazepam, 168
- Clozapine, 108t
- Cocaine, 16
- Codeine, 108t-109t
- Cognitive therapy, 227, 228
- Communicating with patient, 45-54
 about alcohol use, 51
 about antidepressants, 49-51, 57-58, 58t
 about clinical trials, 57-58, 58t
 educating about depression, 47, 49
 patient questions and sample responses, 48t, 49-54
 questions to ask in diagnosis, 35-39
 suicide risk assessment and communication, 45-47, 46t
 terminology used for depressed mood, 42t
- Comorbidities, 42, 43, 213, 214t
 use of antidepressants in treating, 157, 160, 166t-167t, 235
- Compliance (with antidepressant therapy), 60, 60t
- Concentration/attention, 13, 14t
 in different types of affective disorders, 15t
- Confusion, 88t, 90t, 92t, 96t, 180, 245
 drug interactions and (case study), 218-219
 treatment options for, 245
- Constipation, 88t, 90t, 92t, 94t, 95t, 96t, 245
 treatment options for, 245
- Coronary artery disease, 25, 25
 comorbidity with depression, 42, 43
- Cortex, 63, 64-65, 64, 66, 67-68
- Cortical-striatal-pallidal-thalamic circuits, 63, 64
- Cortisol, 69
- Cost. See also *STEPS criteria for specific drugs*.
 of antidepressants, 57, 124t
 of depression, 19, 22t, 25-26, 26
 of treating adverse effects or overdose, 143
- Counseling, empathic, 48
- CP-101606, 141, 232
- CRF-ACTH, 72t
- CRF antagonists, 232
- Cyclosporine, 109t
- Cymbalta. See *Duloxetine*.
- CYP enzymes. See *Cytochrome P450 (CYP) enzymes*.
- Cyproheptadine (Periactin), 245, 248
- Cytochrome P450 (CYP) enzymes, 106-111. See also *specific antidepressants*.
 antidepressants and, 106-111, 107, 108t-110t
 best alternatives among, 111, 215
 newer antidepressants, 110t, 215
 drug interactions and, 106-111, 108t-109t, 137, 214, 215-216
 genetic variants of, 177-178, 181, 202
 inhibition of, 107, 108t-110t
 major CYP enzymes, 107-109
 pharmacokinetic interactions, understanding of, 111
 SSRIs and, 106-107, 107, 111, 155, 168-169
- Cytochrome P450 (CYP) enzymes (*continued*)
 substrates for (drug-drug interactions), 106-111, 108t-109t
 testing for effects on, 108t-110t, 109-111
 "victim" drugs and, 168, 187, 215-216
- Cytokines, 69
- Death, thoughts of, 14t. See also *Suicide*.
- Delusion, 47
- Dental hygiene, 247
- Depression. See also *Clinical depression*.
 as a syndrome, 12-13, 139
 atypical, 13
 brain regions involved in, 63-69, 66
 as cause of physical and life problems, 32-33
 cost of, 19, 22t, 25, 26
 early warning signs of, 204
 forms of, 13
 impact of, 26
 key facts about, 19, 22, 251t
 myths about, 11
 patients' questions about, 48t, 49-54
 prevalence of, 11, 19
 progression of, 32-34, 32, 33
 reactive, 59
 recurrence of, 19, 21, 204-205
 risk factors for, 26-28, 27t
 season onset of, 209-210
 symptoms of, 12-15, 14t, 15t
 terms used for depressed mood, 42t
 treatment algorithm, 203
 treatment-resistant, 243
 unrecognized/undertreated, 11
- Desipramine (Norpramin). See also *Norepinephrine selective reuptake inhibitors (NSRIs)*.
 action mechanism, 80t, 84t
 action sites, 99, 100-102, 104
 in combination therapy, 240
 CYP enzymes and, 108t
 dosage, 133, 146t
 starting, 146t
 frequency of prescriptions for, 156t
 from metabolism of imipramine, 160
 relative binding affinity, 99, 104
 sexual function and, 138
 STEPS criteria for, 126t
 tolerability, 160
- Desvenlafaxine (Pristiq), 78, 79. See also *Serotonin and norepinephrine reuptake inhibitors (SNRIs)*.
 action mechanism, 80t, 84t, 97
 action sites, 103
 as active metabolite of venlafaxine, 177
 adverse effects, 90t-91t, 95t
 CYP enzymes and, 110t, 175
 dosage, 145, 147t, 177
 starting, 144, 145
 drug class of, 80t
 drug interactions with, 175
 efficacy, 166t

- Desvenlafaxine (Pristiq) (*continued*)
 frequency of prescriptions for, 150-157, 156t
 relative binding affinity, 103
 safety, 175
 STEPS criteria for, 128t
 Desyrel. See *Trazodone*.
- Development of newer antidepressants. See *Antidepressant drug development*.
- Dextromethorphan, 109t
- Diabetes, 69
 comorbidity with depression, 42, 43, 214t
- Diagnosis, 11-17, 31-43, 56. See also *Communicating with patient*.
 algorithm for, 36-37
 basis for, 31
 bipolar vs unipolar disorder, 15t, 16-17
 clinical grounds for, 31
 criteria for, 12, 13, 14t
 critical variables in, 12t
 depression as cause vs result of life problems, 32-33
 differential, 39-42
 DSM-IV criteria, 13, 14t
 early, value of, 19, 20, 21
 genetics and, 32-33, 34
 history
 family, 12t, 26-27, 27t, 39-40
 medical, 31, 39
 patient, 39, 40-42
 of present illness, 39
 laboratory tests in, 31, 40
 manic (bipolar)-depression vs unipolar depression, 15t, 16-17
 medical causes, ruling out, 15-16, 39-40
 medications, 39
 misdiagnosis, 114
 patient behavior and, 31, 40, 41t, 42t
 patient denial of symptoms, 33
 patient presentation, 31
 physical examination, 31, 39
 physical observation, 40, 42t
 in primary-care setting, 11-12, 31-43
 questions to ask the patient, 35-39
 signs and symptoms, 12-15, 14t, 15t, 31
 of different affective episodes, 15t
 duration of, 35, 39, 59
 social history, 39
 somatization disorder and, 39-40, 42-43
 steps in, 35, 36-37
 treatment decision and, 42-43
- Diagnostic and Statistical Manual, 4th Ed, Text Revision (DSM-IV-TR)*,
 depression criteria in, 13, 14t
- Diaphoresis, 161, 245
 treatment options for, 245
- Diarrhea, 88t, 90t, 92t, 94t, 245
 treatment options for, 245
- Diazepam, 108t, 109t
- Disability, due to depression, 25-26, 26
- Divorce, 27, 27t
- Dizziness, 88t, 90t, 92t, 94t, 95t, 96t, 180, 246
 treatment options for, 246
- Dopamine, 72t
 as cause of depression, 16
 uptake pump, blockade or antagonism of, 84t, 86t
- Dopamine agonists, 238
- Dopamine and norepinephrine reuptake inhibitors, 80t, 185-189. See also *specific drugs*.
 action mechanism, 185
 advantages of, 185-186
 in combination therapy, 240
 disadvantages of, 186-189
 dosage, 147t, 186-187
 drug interactions with, 187-188
 drugs in this class, 80t-81t, 185
 frequency of prescriptions for, 156t
 STEPS criteria for, 131t, 185-189
- Dorsal raphe, 67-68
- Dorsolateral prefrontal cortex (DLPFC), 65, 72
- Doxepin (Sinequan). See also *Mixed reuptake and neuroreceptor antagonists*.
 action mechanism, 80t
 dosage, 146t
 drug interactions with, 136
 frequency of prescriptions for, 156t
- Drowsiness, 88t, 90t, 92t, 94t, 95t, 96t, 246-247
 treatment options for, 246-247
- Drug abuse, 39
- Drug classes. See *Antidepressant drug classes*.
- Drug development, rational, 79-82. See also *Antidepressant drug development*.
- Drug-drug interactions, 106, 108t-110t, 136, 211-222. See also *specific drugs*.
 annual publications on, 213
 case studies on, 216-221
 epilepsy and seizure risk, 220-221
 Parkinsonism and confusion in the elderly, 218-219
 sudden death, 216-218
 different presentations of, 215-216
 drug clearance and, 215-216
 percentage of patients taking multiple drugs, 212t
 prediction using pharmacodynamics, 84t-85t, 214
 “therapeutic” (augmentation strategies), 235-239
 two mechanisms for, 213-214
- Drug therapies, as cause of depression, 16, 39
- Dry mouth, 88t, 90t, 92t, 95t, 96t, 247
 treatment options for, 247
- DSM-IV, depression criteria in, 13, 14t
- Duloxetine (Cymbalta), 78, 79. See also *Serotonin and norepinephrine reuptake inhibitors (SNRIs)*.
 action mechanism, 80t
 action sites, 103
 adverse effects, 90t-91t, 95t
 CYP enzymes and, 108t, 110t, 175
 dosage, 147t, 177
 drug class of, 80t
 drug interactions with, 175
 efficacy, 166t
 frequency of prescriptions for, 150, 156t
 relative binding affinity, 103
 safety, 175
 withdrawal from, 115

- Duration
of antidepressant trial, 56, 205-209, 223-224
of depression, recovery rate and, 20
- Dyslipidemia, 69
- Dyspepsia, 88t, 90t, 92t
- Economic/social cost of depression, 19, 22t, 25-26, 26
- ECT. See *Electroconvulsive therapy*.
- Edronax (roboxetine), 78
- Education. See *Patient education*.
- Effexor. See *Venlafaxine*.
- Efficacy of antidepressant drug therapy, 124t, 138-143. See also *STEPS criteria*.
drug interactions presenting as decrease in, 215
maintenance efficacy, 140, 142
overall acute efficacy, 139, 140
prophylactic efficacy, 140, 142-143
rate of response, 139-141
unique spectrum of efficacy, 139, 141-142
- Elavil. See *Amitriptyline*.
- Elderly population
antidepressant drug therapy in, 214
drug interaction likelihood for, 212t, 214, 221-222
drug interactions, case study on, 218-219
norfluoxetine half-life in, 249
- Electroconvulsive therapy (ECT), 203, 242, 242-243
- Emotional complaints, diagnosis and, 31
- Empathic counseling, 48
- Emsam. See *Selegiline transdermal system*.
- Enantiomers (citalopram and escitalopram), 169-172, 171t, 172t
- Energy, in different types of affective disorders, 15t
- Epilepsy, 214t, 220-221
- Erex (yohimbine), 248
- Erythromycin, 109t
- Escitalopram (Lexapro), 78, 79, 80t. See also *Serotonin selective reuptake inhibitors (SSRIs)*.
action mechanism, 80t, 84t, 97
action sites, 99, 102
as active enantiomer of citalopram, 169
adverse effects, 88t-89t, 94t
in combination therapy, 240
CYP enzymes and, 107, 110t, 111, 169, 174, 178
dosage, 146t
starting, 144, 146t, 164-165
efficacy, 166t, 171t
compared with other drugs, 128t, 155
frequency of prescriptions for, 156t, 227
relative binding affinity, 99, 102
STEPS criteria for, 127t
switching from, 234-235
vs citalopram, 169-172, 171t, 172t
response rate, 173
withdrawal syndrome, 115, 168
- Estrogen, depression and, 27
- Family history, 12t, 26-27, 27t, 39-40
of bipolar disorder, 17, 242
of major depression, 26-27, 27t
- Fast Na⁺ channel blockade
drugs with this action, 84t, 100-101, 163
physiological consequences of, 86t
TATCA effect on, 100-101, 136
- Fatigue, 13, 14t, 31
as antidepressant side effect, 88t, 90t, 92t, 94t, 96t, 247
treatment options for, 247
- Fear conditioning, amygdala and, 68
- Financial problems, 31
- Flatulence, 88t, 90t, 92t
- Fluoxetine (Prozac). See also *Serotonin selective reuptake inhibitors (SSRIs)*.
action mechanism, 80t, 106, 127t
action sites, 102
active metabolite (norfluoxetine), 162, 249
adverse effects, 88t-89t, 94t, 249
CYP enzymes and, 107, 108t, 110t, 111, 137, 162, 168, 175, 187-188, 215-216, 237
discontinuance of, 113
dosage, 146t, 164
starting, 144, 146t
drug interactions with, 131t, 159, 168, 179, 181-182, 218-221
efficacy, 166t
compared with other drugs, 128t, 130t, 184
in elderly patients, 249
frequency of prescriptions for, 150, 155, 156t
half-life of, 113, 162, 249
launch date of, 78
Prozac Weekly, 78
as racemate, 169
relative binding affinity, 102
suicide risk ratio, 135
withdrawal syndrome, 115, 116, 116t, 168
- FLUSH mnemonic, 115t
- Fluvoxamine (Luvox). See also *Serotonin selective reuptake inhibitors (SSRIs)*.
action mechanism, 80t
action sites, 102
adverse effects, 88t-89t, 94t
CYP enzymes and, 107, 108t, 110t, 111, 137, 168
dosage, 146t
starting, 144, 146t
drug interactions with, 168
frequency of prescriptions for, 113, 156t
half-life of, 113
relative binding affinity, 102
withdrawal syndrome, 115, 168
- Follow-up visits
in continuation therapy, 205-209
in initial treatment, 201-205
- Four "D's" of antidepressant treatment, 56
- GABA, 72t
- GADE mnemonic, 82-87
- Gastrointestinal adverse effects, 180
- Gender differences, in depression risk factors, 26, 27t
- Generalized anxiety disorder (GAD), 166t-167t
- Genetics, depression and, 32-33, 34, 71, 72, 82-83
- Globus pallidus, 63, 64

- Glucocorticoids, 67, 70, 70
 antagonists, 232
- Glutamate, 67-68, 72t
- Guilt, feelings of, 14t, 45, 49
- Half-life, 112-113. See also *specific drugs*.
 adverse effects and, 248
- Hallucinations, 47
- Haloperidol, 108t, 109t
- Hamilton Depression Rating Scale (HDRS), 58t, 65, 134, 205, 206-209, 223, 243-244
- Headache, 31
 as antidepressant side effect, 88t, 90t, 92t
 migraine, tertiary amine TCAs for, 157
- Heart failure, depression and, 25, 25
- Hippocampus, 65, 76-78
- Histamine, 72t
- Histamine-1 receptor blockade
 adverse effects of, 246, 247
 drugs with action on, 84t, 98, 183
 physiologic consequences of, 84t, 106, 136
 TCA effect on, 136
- History
 family, 26-27, 27t, 39-40
 medical, 31, 39
 patient, 39, 40-42
 of present illness, 39
 social, 39
- HIV, comorbidity with depression, 43
- Hopelessness, feelings of, 45
- Hormone levels, depression and, 27
- Hospitalization, decisions about, 45, 47, 48
- HPA (hypothalamic-pituitary axis), 68, 69, 70
- Human immunodeficiency virus, 43
- Hydrocortisone, 68
- Hydroxynefazodone, 181
- Hyperphagia, 247-248
- Hypersomnia, 14t
- Hypertension, 69, 133
 antihypertensive drugs, 16, 39, 136
- Hypertensive crisis, 136, 161, 174-175, 190, 191-192
- Hypomania, 15t, 16, 17, 242
- Hypotension, 158-159, 192
- Hypothalamic-pituitary axis (HPA), 68, 69, 70
- Imipramine (Tofranil-PM). See also *Mixed reuptake and neuroreceptor antagonists*.
 action mechanism, 80t, 98
 action sites, 98, 104
 adverse effects, 92t-93t, 96t
 cost of, 160
 CYP enzymes and, 108t
 dosage, 146t
 drug interactions with, 160
 early development of, 77, 100-101
 efficacy of, 127t, 136, 142-143, 157, 193
 frequency of prescriptions for, 156t
 metabolism of (conversion to desipramine), 160
- Imipramine (Tofranil-PM) (*continued*)
 prophylactic efficacy of, 142-143
 relative binding affinity, 104, 160
 STEPS criteria for, 125t
 switching to, 234-235
- Individual variability in drug responses, 82-87, 137, 202
- Insomnia, 14t, 31, 248
 as antidepressant side effect, 88t, 90t, 92t, 94t, 95t, 98, 248
 tertiary amine TCAs for, 157
 treatment options for, 248
- Interaction (patient behavior), 41t
- Interaction of drugs. See *Drug-drug interactions*.
- Interindividual variability, 82-87, 137, 202
- Interleukins, 69
- Irritability, 31, 40, 41t
- Ketamine, 141, 232
 "Kindling" phenomenon, 32
- Laboratory testing, in diagnosis, 31, 40
- Latency of response, 40, 41t
- Lateral orbital prefrontal cortex (LOPFC), 64
- Lexapro. See *Escitalopram*.
- Life complaints, 31
- Limbic system, 67-68
- Lithium
 antidepressants with, 229, 236, 237
 for bipolar disorder, 40
 in STAR*D study, 227, 229, 236
- Liver failure, 179
- Liver function tests, 40
- Locus coeruleus, 67-68
- Lomotil, 245
- Lorazepam, 247
- Ludiomil. See *Maprotiline*.
- Luvox. See *Fluvoxamine*.
- MADRS. See *Montgomery-Asberg Depression Rating Scale*.
- Magnetic resonance imaging (MRI), 67
- Major depression. See *Clinical depression*.
- Major depressive disorder (MDD). See *Clinical depression*.
- Malignancies, 16
- Manic-depressive disorder. See *Bipolar disorder*.
- Manic episodes, hypomania, 15t
- MAOIs. See *Monoamine oxidase inhibitors*.
- Maprotiline (Ludiomil). See also *Norepinephrine selective reuptake inhibitors (NSRIs)*.
 action mechanism, 80t
 dosage, 146t
- Marriage, marital status as a risk factor, 27, 27t
- MCPP (meta-chlorophenylpiperazine), 181, 182
- Medical conditions causing depression, 15-16, 39-40
- Medical history, 31, 39
- Medical illness
 comorbid with depression, 42, 43, 213, 214t
 drug-drug interaction likelihood and, 211-212, 212t
- Medications
 as cause of depression, 16, 39

Medications (*continued*)
 interactions among, 42
 multiple medication use, 211-222

Melancholic depression, 13. See also *Clinical depression*.
 onset age in, 13
 signs and symptoms of, 13, 14t, 15t

Memory problems, 31

Meta-chlorophenylpiperazine (mCPP), 181, 182

Methadone, 108t

Methylphenidate, 238

Mianserin, 183

Mibefradil (Posicor), 109

Midazolam, 109t

Mirtazapine (Remeron), 183-185
 action mechanism, 80t, 84t, 183
 action sites, 105
 advantages of, 98, 183-184
 adverse effects, 92t-93t, 96t, 98, 144, 183-184
 sedation, 144, 202, 246-247
 for anorexia, 245
 combined with venlafaxine, 227, 240
 disadvantages of, 184-185
 dosage, 147t, 150
 starting, 144, 147t
 drug interactions with, 183
 efficacy, 140, 184
 frequency of prescriptions for, 150, 156t
 launch date of, 78
 relative binding affinity, 105
 response rate, 140
 sexual function and, 138
 in STAR*D study, 227, 229
 STEPS criteria for, 130t, 183-185
 tolerability, 184-185

Mixed reuptake and neuroreceptor antagonists, 80t, 157-160. See also *Tertiary amine tricyclic antidepressants*.
 advantages of, 157-158
 adverse effects, 158-159
 cost of, 158, 160
 disadvantages of, 158-159
 dosage, 146t, 158, 159
 starting, 159
 upward titration of, 159
 drug interactions of, 158
 drugs in this class, 80t-81t
 frequency of prescriptions for, 156t
 indications for, 157-158, 160
 overdose, 158
 response rates, 157
 safety, 158
 STEPS criteria for, 125t, 157-159
 tolerability, 158-159

Molindone, 218-219

Monoamine oxidase inhibitors (MAOIs), 77, 80t, 189-192. See also *Selegiline transdermal system*.
 A and B forms of, 190
 action mechanism, 80t, 86t
 advantages of, 190

Monoamine oxidase inhibitors (MAOIs) (*continued*)
 adverse effects, 192
 in combined therapy, 161, 174-175, 240
 combinations to be avoided, 241
 disadvantages of, 190-192
 dosage, 147t
 drug interactions of, 106, 136, 190
 drugs in this class, 80t-81t, 84t
 frequency of prescriptions for, 156t, 189
 half-lives and, 112
 hypertensive crisis and, 190, 191-192
 indications for, 190, 192
 STEPS criteria for, 132t, 190-192
 tyramine and, 189, 190, 191

Montgomery-Asberg Depression Rating Scale (MADRS), 171t, 177, 236, 237

Mood stabilizers, 40, 242

Mood symptoms, 12-13, 14t, 31
 in different types of affective disorders, 15t
 questioning the patient about, 35-39
 terms used to describe, 42t

Motivation, 13

Multiple medication use (MMU), 211-222

Muscarinic acetylcholine receptor blockers
 adverse effects of, 245, 247
 drugs with this action, 84t
 physiologic consequences of, 86t, 136
 TCA effect on, 136

Myocardial infarction, depression and, 25, 25, 43, 214t

Myths about depression, 11

N-methyl-D-aspartate. See *NMDA*.

Nardil (phenelzine), 80t, 147t

Nausea, 88t, 90t, 92t, 94t, 95t, 97, 164, 175, 248
 treatment options for, 248

Nefazodone (Serzone), 80t, 178. See also *Serotonin-2A receptor blocker and weak serotonin uptake inhibitors*.
 action mechanism, 80t, 84t
 action sites, 105
 active metabolites, 181-182
 advantages of, 178-179
 adverse effects, 92t-93t, 96t, 98, 179
 vision disturbance, 248
 black box warning on, 178, 182
 CYP enzymes and, 110t, 137, 181-182
 disadvantages of, 179-182
 dosage, 147t, 150, 179-180
 ascending titration of, 180
 starting, 144, 147t, 179-180
 drug interactions with, 179
 efficacy, 180
 frequency of prescriptions for, 113, 150, 156t
 half-life of, 113
 indications for, 182
 launch date of, 78
 nonlinear pharmacokinetics of, 180-181
 relative binding affinity, 105
 safety, 179
 sexual function and, 138

- Nefazodone (Serzone) (*continued*)
 STEPS criteria for, 129t
 tolerability, 179-180
 withdrawal from, 117
- Nervousness, 88t, 90t, 92t, 94t, 95t, 96t, 248
 treatment options for, 248
- Neuroanatomy, 63-67
- Neurogenesis, 71, 72t
- Neurokinins, 72t
- Neuroscience basis of depression, 63-75, 72t
 amygdala, 65, 66, 68
 anatomy and physiology, 63-67, 64, 66
 circuits, 63, 64
 hippocampus, 65, 76-78
 HPA dysfunction, 68, 69, 70
 neurotransmitters and receptors, 67-72, 72t
- Neurotransmitters and their receptors, 67-72, 72t
- Newer antidepressants, development of. See *Antidepressant drug development.*
- NMDA receptors, 68, 139
 antagonists of, 68, 141, 232
- Noncompliance (with antidepressant therapy), 60, 60t, 61t
- Norepinephrine, 67-68, 72, 72t
 receptor blockade or antagonism, 84t, 86t, 97
- Norepinephrine (therapy with), as cause of depression, 16
- Norepinephrine selective reuptake inhibitors (NSRIs), 80t, 100-102, 161-163.
- See also *Dopamine and norepinephrine reuptake inhibitors; specific drugs.*
- action mechanism, 161
 advantages of, 161-162
 adverse effects, 138
 combined with other antidepressants, 141, 161, 240
 cost of, 163
 disadvantages of, 163
 dosage, 133, 162
 drug interactions of, 161
 drugs in this class, 80t-81t
 efficacy, 162
 frequency of prescriptions for, 156t
 half-life, 162
 hypertensive crisis and, 161
 safety, 161, 163
 selection of, 163
 selectivity of, 161
 sexual function and, 138
 STEPS criteria for, 126t, 161-163
 TDM for, 162
 tolerability, 161
- Norepinephrine uptake pump, 84t, 86t
- Norflouxetine, 113, 162, 249
- Norpramin. See *Desipramine.*
- Nortriptyline (Pamelor, Aventyl). See also *Norepinephrine selective reuptake inhibitors (NSRIs).*
 action mechanism, 80t
 action sites, 104
 CYP enzymes and, 108t
 dosage, 146t
 fluoxetine with, 106
 frequency of prescriptions for, 156t
- Nortriptyline (Pamelor, Aventyl) (*continued*)
 relative binding affinity, 104
 in STAR*D study, 227, 229
- NSRIs. See *Norepinephrine selective reuptake inhibitors.*
- Obesity, 69
- Obsessive-compulsive disorder (OCD), 64, 166t-167t
- Olanzapine, 108t
- Omeprazole, 108t
- Onset age. See *Age of onset*
- Orthostatic hypotension, 158-159
- Overdose
 of antidepressant, 123-124
 of tertiary amine TCAs, 158
- Pain, chronic, 157, 160, 214t
- Pamelor. See *Nortriptyline.*
- Panic disorder, 64, 166t-167t
- Parkinson's disease
 bupropion for, 186, 189
 comorbidity with depression, 43, 214t
 drug interactions, case study, 218-219
 psychostimulants and, 238
- Parnate. See *Tranylcypromine.*
- Paroxetine (Paxil). See also *Serotonin selective reuptake inhibitors (SSRIs).*
 action mechanism, 71, 80t, 169
 action sites, 102
 adverse effects, 88t-89t, 94t, 164, 176, 218-219
 CYP enzymes and, 107, 108t, 110t, 111, 115-116, 137, 162, 174, 178-179, 181-182, 187-188, 215, 237
 dosage, 145, 146t
 starting, 144, 146t
 efficacy, 166t
 compared with other drugs, 125t, 127t, 157, 227
 frequency of prescriptions for, 150, 155, 156t
 launch date of, 78
 relative binding affinity, 102
 suicide and, 135
 sustained release (Paxil-CR), 78
 withdrawal syndrome, 115, 116, 116t, 168
- Pathophysiology of depression. See *Neuroscience basis of depression.*
- Patient, 45-54
 communicating about clinical trials, 57-58, 58t
 communicating with, 45-54
 compliance/noncompliance with treatment, 60, 60t, 61t
 concerns about antidepressants, 49-51, 57
 involvement in treatment, 56, 201, 202
 questions about depression (and sample responses), 48t, 49-54
 suicide and antidepressants, communicating about, 53-54
 suicide ideation, inquiring about, 46-47
 suicide risk, assessing, 45, 46t
- Patient education
 about adverse effects (dizziness), 246
 about antidepressant drug therapy, 60-61
 about depression, 47, 49
 about recurrence risk (for depression), 204-205, 209
 continuation of, 203
 at treatment initiation, 201-205

- Patient-oriented approach, 55-56
- Paxil. See *Paroxetine*.
- Periactin (cyproheptadine), 245, 248
- Periodontal disease, 159, 247
- Perphenazine, 108t
- Personalized medicine, 82
- Pharmacodynamics
- drug-drug interactions, 106, 136
 - pharmacokinetics and individual response to drugs and, 82-87, 137
 - principles of antidepressants, 97-106, 111-112
- Phenelzine (Nardil), 80t, 147t. See also *Monoamine oxidase inhibitors (MAOIs)*.
- Phenytoin, 108t
- Physical examination, 31, 39
- Physical observation, in diagnosis, 40, 42t
- Pindolol, 239
- Pituitary gland, 69, 70
- Placebo response, 58-59
- Posicor (mibefradil), 109
- Post-traumatic stress disorder (PTSD), 64, 166t-167t
- Postpartum depression, 27, 27t
- Pregnancy, depression risk in, 27, 27t
- Premenstrual dysphoric disorder (PMDD), 166t-167t
- Prevalence of depression, 11, 19
- in specific medically ill populations, 214t
- Priapism, 138
- Price. See *Cost*.
- Primary-care physician. See also *Communicating with patient*.
- diagnosis and, 11-12, 31-43
 - role as advisor to patient, 55
- Primary-care setting, depression diagnosis in, 11-12, 31-43. See also *Diagnosis*.
- Pristiq. See *Desvenlafaxine*.
- Prognosis of depression, 25, 28
- Progression of depression, 32-34, 32, 33
- Prophylactic efficacy of antidepressants, 140, 142-143
- Protriptyline (Vivactil), 80t. See also *Norepinephrine selective reuptake inhibitors (NSRIs)*.
- Prozac. See *Fluoxetine*.
- Psychiatrist, referral to, 249
- Psychomotor agitation or retardation, 14t, 186
- Psychomotor restlessness, 40
- Psychosis
- amygdala involvement in, 68
 - anti-psychotic effect of imipramine, 98
 - assessment of patient for, 45, 47
- Psychostimulants, 238
- Psychotherapy (cognitive therapy), 227, 228
- Putamen, 63, 64
- Questions
- to ask, in diagnosis, 35-39
 - of patients (with sample responses), 48t, 49-54
- Quetiapine, 109t
- Racemate vs pure enantiomer, 169-172
- Rating scales for depression. See *Scales, rating*.
- Reactive depression, 59
- Reactivity, 15t
- Reboxetine, sexual function and, 138
- Receptors
- blockade or antagonism of, 86t
 - and genetics in depression, 69-71
 - indirect agonists, antidepressants as, 97
- Recurrence of depression, 19, 20, 21, 32-34
- adverse effects of successive episodes, 32-34, 32
 - cumulative probability of, 33
 - early warning signs, education on, 204
 - patient education about, 204-205, 209
 - risk after one depressive episode, 204
 - risk after two depressive episodes, 209
- Relapses, 19, 21
- Relative binding affinity, 87, 99, 102-105
- REM sleep, 97
- Remeron. See *Mirtazapine*.
- Remission with antidepressants, 58, 58t
- rate for citalopram (Celexa), 59, 61
 - response vs, 58t
 - in STAR*D study, 230-233, 231t
 - in treatment algorithm, 203, 205
- Renal disease, depression and, 214t
- Renal function tests, 40
- Response to antidepressants
- categories of, 203, 205
 - defined, 58, 58t
 - rate of response, 139-141
 - remission vs, 58t
 - in treatment algorithm, 203
- Responsiveness of patient, in diagnosis, 41t
- Risk factors for depression, 26-28, 27t
- Risk of recurrence, 33, 204, 209
- Risperidone, 108t
- Roboxetine (Edronex), 78, 163
- SAD PERSONS scale, 46t
- Safety, in antidepressant drug therapy, 123-137. See also *STEPS criteria*.
- acute therapeutic index, 123-133
 - drug interactions, 136-137
 - long-term safety, 133
 - overdose issues, 123-124
 - suicidality and, 134-136
- Scales, rating
- Hamilton Depression Rating Scale, 58t, 65, 134, 205, 206-209, 223
 - Montgomery-Asberg Depression Rating Scale, 177, 236, 237
 - self-report scales, 205
 - Sheehan Disability Scale, 236, 237
 - zero to ten analog scale, 223, 224
- Season onset of depression, 209-210
- Secondary amine TCAs, 161-163. See also *Norepinephrine selective reuptake inhibitors*.
- Sedation, as antidepressant side effect, 159, 180, 184-185, 202
- Sedatives, 16
- Seizures, 89, 133, 144, 145, 186-187
- drug interactions, case study on, 220-221
- Seldane (terfenadine), 109
- Selective serotonin reuptake inhibitors. See *Serotonin selective reuptake inhibitors (SSRIs)*.

Selegiline transdermal system (STS; Emsam), 78, 79, 190-192.

See also *Monoamine oxidase inhibitors (MAOIs)*.

action mechanism, 80t, 84t, 190

adverse effects, 92t-93t, 96t

dosage, 147t

efficacy, 167t

half-life and, 112

irreversible inhibition of MAO, 111-112, 191

STEPS criteria for, 132t

Self-esteem, 31

Sequential Treatment Alternatives to Relieve Depression. See *STAR*D study*.

Serology, 40

Serotonin (5-HT), 67, 72, 72t

as cause of depression, 16

receptors, blockade or antagonism of, 84t, 86t, 97-98, 239

receptors, indirect agonism of, 97-98

syndrome, 106, 136, 191

uptake inhibition, 84t, 136

Serotonin (5-HT_{2A} and 5-HT_{2C}) and alpha norepinephrine receptor blocker.

See *Mirtazapine*.

Serotonin-2A receptor blocker and weak serotonin uptake inhibitors, 80t, 178-182.

See also *Nefazodone*; *Trazodone*.

action mechanism, 178-179

active metabolites, 181-182

advantages of, 179

CYP enzymes and, 179, 181-182

disadvantages of, 179-182

dosage, 147t, 179-180

drug interactions with, 179

drugs in this class, 80t-81t, 178

efficacy, 180

safety, 179

STEPS criteria for, 129t, 179-182

tolerability, 179-180

Serotonin and norepinephrine reuptake inhibitors (SNRIs), 70, 80t, 174-178.

See also *specific drugs*.

action mechanism, 80t, 84t, 97

action sites, 101, 103

advantages of, 174-176

adverse effects, 90t-91t, 95t, 97-98, 176, 245, 248

combinations to be avoided, 241

combined with other antidepressants, 174-175, 240

CYP enzymes and, 177-178

disadvantages of, 176-177

dosage, 145-150, 147t, 174, 175-177

starting, 144, 145-150, 175-176

drug interactions with, 106, 174-175

drugs in this class, 80t-81t, 84t, 174

efficacy, 175

frequency of prescriptions for, 150-157, 156t

hypertensive crisis and, 174-175

relative binding affinity, 103

safety, 174-175

STEPS criteria for, 128t, 174-177

summary, 178

switching to, 235

tolerability, 175

withdrawal syndrome, 114, 115t, 116

within class differences, 177-178

Serotonin reuptake pump, 71, 97

Serotonin selective reuptake inhibitors (SSRIs), 80t, 101, 163-174.

See also *specific drugs*.

action mechanism, 97

action sites, 102

advantages of, 164

adverse effects, 88t-89t, 94t, 97-98, 163-164, 165, 245

in combination therapy

combinations to be avoided, 241

with NSRIs, 141, 240

two SSRIs combined, 240

CYP enzymes and, 106-107, 107, 111, 155, 163, 168-169

best options for, 169, 174

disadvantages of, 165-173

dosage, 145, 146t, 164

starting, 144, 145, 164

upward titration of, 164

drug interactions with, 106-107, 155, 164, 168-169

drugs in this class, 80t-81t

efficacy, 163, 165

failure of, alternative medications, 157, 161

frequency of prescriptions for, 150, 156t, 163

half-lives, 165-168

individual variation in response to, 165, 174

relative binding affinity, 102

safety, 164

serotonin reuptake pump (5-HTT) and, 71

sexual dysfunction and, 164, 165, 248

STEPS criteria for, 127t, 164-165

summary, 173-174

switching to another, 235

switching to SNRI from, 235

tolerability, 164

withdrawal syndrome, 114, 115t, 116, 165-168

responses for, 168

Serotonin syndrome, 106, 136, 191

Serotonin (therapy with), as cause of depression, 16

Serotonin transporter gene (SLC6A4), 33, 34, 71

Serotonin transporter protein (5-HTT, serotonin reuptake pump), 71, 97

Sertraline (Zoloft). See also *Serotonin selective reuptake inhibitors (SSRIs)*.

action mechanism, 80t

action sites, 102

adverse effects, 88t-89t, 94t

CYP enzymes and, 107, 110t, 111, 169

dosage, 146t

starting, 144, 146t

efficacy, 167t

frequency of prescriptions for, 156t

launch date of, 78

as racemate, 169

relative binding affinity, 102

in STAR*D study, 227, 228

suicide and, 135

withdrawal syndrome, 115, 116, 116, 168

Serzone. See *Nefazodone*.

Sex drive, 13

in different types of affective disorders, 15t

Sexual dysfunction, 97, 98, 138, 164, 165, 175, 186, 248-249
 treatment options for, 248-249
Sheehan Disability Scale (SDS), 236, 237
Signs and symptoms. See *Symptoms*.
Sildenafil (Viagra), 248
Simplicity, in antidepressant therapy, 124t, 144-150. See also *STEPS criteria*.
Sinequan. See *Doxepin*.
SLC6A4 gene, 33, 34
Sleep patterns, 13, 14t. See also *Drowsiness; Insomnia*
 antidepressant effects on, 88t, 90t, 97-98, 247
 in different types of affective disorders, 15t
 fatigue as a symptom of, 247
 trazodone as aid for, 247
Smoking. See *Cigarette smoking*.
SNRIs. See *Serotonin and norepinephrine reuptake inhibitors*.
Social anxiety disorder, 166t-167t
Social history, in diagnosis, 39
Social support deficit, 46t, 60
Social withdrawal/isolation, 31
 suicide risk and, 46t
Sodium channels. See *Fast Na⁺ channel blockade*.
Somatic complaints, 31
Somatization disorder, 39-40, 42-43
Specific serotonin and adrenergic receptor blocker. See *Mirtazapine*.
SSRIs. See *Serotonin selective reuptake inhibitors*.
STAR*D study, 28, 61, 139, 141-142, 186, 193, 226-241
 augmentation strategies in, 236
 design of, 226-230, 228-229
 levels in, 226-230, 228-229
 nonremitting patients in, 230-233, 231t
 results of, 230-233, 231t
STEPS (safety-tolerability-efficacy-payment-simplicity) criteria, 56, 123-153,
 124t, 125t-132t
 for dopamine and norepinephrine reuptake inhibitors, 131t, 185-189
 efficacy, 138-143
 for mixed reuptake and neuroreceptor antagonists, 125t, 157-159
 for monoamine oxidase inhibitors, 132t, 190-192
 for norepinephrine selective reuptake inhibitors, 126t, 161-163
 price, 143
 safety, 123-137, 124t
 for serotonin-2A receptor antagonists and weak serotonin reuptake inhibitors,
 129t, 179-182
 for serotonin and alpha-2 norepinephrine receptor antagonists, 130t
 for serotonin and norepinephrine reuptake inhibitors (SNRIs), 128t, 174-177
 for serotonin selective reuptake inhibitors (SSRIs), 127t, 164-165
 simplicity, 144-150
 for TCAs, 123-124
 tolerability, 137-138
Steroids, 39
Stool softeners, 245
Stress
 persistent, depression and, 72
 serotonin transporter and, 33, 34
Stress-Diathesis Model, 34
Stressful life events
 adaptation to, 41t
 attribution of, 49
 increase with recurring episodes, 32, 32

Stressful life events (*continued*)
 low tolerance for, 31, 41t
 as result of depression (vs cause of), 32-33
Striatum, 63, 64, 65, 66
Stroke, 214t
STS. See *Selegiline transdermal system*.
Substance abuse
 causing depression, 16
 depression and, 16, 23
 noncompliance with treatment and, 60
Substance P, 72t, 232
Sugarless gum, 247
Suicide, 19-23, 23t, 134-136
 antidepressants and, 23, 24, 134-136
 black box warning, 135
 children and adolescents, 23, 53-54, 134, 135
 decline in suicide rate with newer, 24, 136
 communicating with patient about, 46-47, 53-54
 depression and, 19-23, 20t, 23t, 46t
 ideation, 14t, 46-47, 134
 antidepressant withdrawal syndrome and, 176
 inquiring about, 46-47
 treatment initiation and, 204
 incidence of, 19, 23t
 mortality costs related to, 19
 previous attempts at, 45, 46t
 risk
 antidepressants and, 53-54, 134-136
 assessing, 45, 46t
 risk factors for, 45, 46t
 SAD PERSONS scale, 6t
 in teenagers, 19, 53-54
Surmontil. See *Trimipramine*.
Symptoms, 12-15, 14t, 15t, 31
 in different affective episodes, 15t
 duration of, 35, 39, 59
 patient denial of, 33
 questioning the patient about, 35-39
Syndrome, depression as, 12-13, 139

Tachycardia, 161, 175
Tacrine, 108t
Targeting, in drug development, 79
TCAs. See *Tertiary amine tricyclic antidepressants*.
TDM. See *Therapeutic drug monitoring*.
Teenagers, suicide and, 19, 53-54
Terfenadine (Seldane), 109
Tertiary amine tricyclic antidepressants (TCAs), 157-160. See also *specific drugs*.
 acute therapeutic index of, 123-124
 advantages of, 98-100, 157-158
 adverse effects of, 158-159
 cost of, 143
 disadvantages of, 158-159
 dosage, 146t, 158, 159
 drug interactions with, 136
 early development of, 77
 efficacy, 140
 prophylactic, 142-143

Tertiary amine tricyclic antidepressants (TCAs) (*continued*)

- frequency of prescriptions for, 156t
- indications for, 157-158, 160
- pharmacology of, 99-100
- polydrug actions, 99, 100, 100t
- relative binding affinity of, 104
- STEPS criteria for, 125t, 157-159

Tertiary amine tricyclic antidepressants (TCAs)

- blood plasma monitoring of, 202
- combined with MAOI, 240
- dosage, 123-124, 145
 - starting, 144
 - therapeutic drug monitoring, 145
- drug interactions and, 136
- safety, 123-124
 - overdose, 123-124
 - ventricular arrhythmias, 101, 124
- serotonin reuptake pump (5-HTT) and, 71
- sexual dysfunction and, 138
- switching to, 235
- TDM for, 145, 158, 159-160, 202, 240
- therapeutic index, narrow, 123-124, 202, 240

Testosterone, topical cream, 248

Thalamus, 63, 64, 65, 66

Therapeutic drug monitoring (TDM), 125t, 145

- for bupropion, 187
- in combination therapy, 240
- for norepinephrine selective reuptake inhibitors, 162
- for tertiary amine TCAs for, 158

Thinking patterns. See *Concentration*.

Thioridazine, 108t

Thyroid function tests, 40

Thyroid hormone, in STAR*D study, 227, 229, 236

Thyroid supplementation, as augmentation strategy, 227, 229, 236, 238

Thyroxine (T₃), 227, 229, 239

Timing of behavior(s), 40, 41t

Tofranil. See *Imipramine*.

Tolerability, in antidepressant drug therapy, 124t, 137-138, 141.

See also *STEPS criteria*.

Tolerance (lowered), diagnosis and, 31, 41t

Tranlycypromine (Parnate), 80t, 240. See also *Monoamine oxidase inhibitors (MAOIs)*.

- action mechanism, 240
- dosage, 147t
- in STAR*D study, 227, 229

Trazodone (Desyrel), 77, 80t, 178. See also *Serotonin-2A receptor blocker and weak serotonin uptake inhibitors*.

- action mechanism, 80t, 98
- CYP enzymes and, 109t
- dosage, 147t
- frequency of prescriptions for, 156t
- priapism from, 138
- as sleep aid, 179

Treatment of depression, 28, 201-210, 251t. See also *Antidepressant drug therapy*.

- advances in, 28
- algorithm for, 203
- communicating with patient in. See *Communicating with patient*.
- decision to treat, 45

Treatment of depression (*continued*)

- duration of episodes, recovery rate and, 20
- early, value of, 19, 20, 21
- follow-up in, 201-209
- “Four D’s” in, 56
- goal of (remission), 58, 60-61
- hospitalization decision in, 45, 47, 48
- initiating outpatient therapy, 48-54, 201-205
- major facts about, 251t
- major variables in, 56
- patient involvement in, 56, 201, 202
- phases of, 138
- planning algorithm, 37
- response vs remission in, 58t
- steps in, 37
- timing of, 42-43
- trial of medication, 43
- undertreatment, 11, 25, 28

Tremors, 161, 175

Triazolam, 109t

Triazolidione, 181

Tricyclic antidepressants. See *Tertiary amine tricyclic antidepressants (TCAs)*.

Trimipramine (Surmontil). See also *Mixed reuptake and neuroreceptor antagonists*.

- action mechanism, 80t
- drug interactions with, 136

Tumors, 67, 214t

Tyramine, monoamine oxidase inhibitors and, 189, 190, 191

Unipolar disorder, 16-17, 20t

- diagnosing, 15t, 16-17
- duration of, 23t
- prevalence of, 23t
- vs bipolar disorder, 15t, 16-17

Urinalysis, 40

Vagus nerve stimulation (VNS), 71, 203, 243-244

Venlafaxine (Effexor). See also *Desvenlafaxine; Serotonin and norepinephrine reuptake inhibitors (SNRIs)*.

- action mechanism, 80t
- action sites, 103
- active metabolite (desvenlafaxine), 177
- adverse effects, 90t-91t, 95t, 175
- blood pressure and, 133, 175
- combined with mirtazapine, 227, 240
- CYP enzymes and, 108t, 110t, 175
- dosage, 133, 145-150, 147t, 174, 175-176
 - ascending, 176, 177
 - dose-response curve, 145-150, 174
 - high-dose, 133, 140, 150, 175
 - IR, XR, 147t
 - starting, 144, 147t, 150, 175-176
- drug interactions with, 175
- efficacy, 140, 167t, 175
- formulations of (IR, XR), 95t, 113, 147t, 156t, 167t, 176
- frequency of prescriptions for, 113, 150
- half-life, 113, 176
- launch date of, 78

Venlafaxine (Effexor) (*continued*)
relative binding affinity, 103
response rate, 140
safety, 175
in STAR*D study, 227, 228-229, 234
suicide and, 135
switching to, 235
withdrawal syndrome, 115, 176

Ventromedial prefrontal cortex (VMPFC), 64, 67, 68, 72

Viagra (sildenafil), 248

“Victim” drugs, CYP inhibition and, 168, 187, 215-216

Visual disturbance, 249
as antidepressant side effect, 89t, 90t, 93t, 96t
treatment options for, 249

Vivactil. See *Protriptyline*.

Warfarin, 108t

Weight changes, 13, 14t, 31
anorexia and, 245
as antidepressant side effect, 93t, 96t, 185

Wellbutrin. See *Bupropion*.

White blood cell count, 184

Withdrawal syndrome, antidepressants, 114-117, 114t, 115t, 116.
See also *specific drugs*.
drug interactions presenting as, 215
responses to, 168
risk factors for, 115

Women, depression risk factors for, 26, 27t

Work Composite Score of Functional Adjustment Scale, 19, 21

Workplace
benefits of remission of depression for, 21
losses/disability due to depression, 25-26, 26

Worthlessness, feelings of, 14t, 31
questions about, 38

Yocon (yohimbine), 248

Yohimbine (Aphrodyne, Erex, Yocon, Yohimex), 248

Yohimex (yohimbine), 248

Zero to ten analog scale, 223, 224

Zoloft. See *Sertraline*.

Zolpidem, 109t

Zyban. See *Bupropion*.